The European Medicines Agency's CHMP Issues Positive Opinion For Genmab-AbbVie Partnered Epcoritamab (Tepkinly) For Relapsed/Refractory Diffuse Large B-cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Epcoritamab (Tepkinly), a drug developed in partnership by Genmab and AbbVie, for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
July 21, 2023 | 8:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive opinion from CHMP for Epcoritamab, developed in partnership with Genmab, could potentially boost AbbVie's market position in the oncology sector.
The positive opinion from CHMP is a significant step towards the approval of Epcoritamab in Europe. This could potentially increase AbbVie's revenues and strengthen its position in the oncology market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
The positive opinion from CHMP for Epcoritamab, developed in partnership with AbbVie, could potentially boost Genmab's market position in the oncology sector.
The positive opinion from CHMP is a significant step towards the approval of Epcoritamab in Europe. This could potentially increase Genmab's revenues and strengthen its position in the oncology market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50